

Supplementary Table 3. Therapeutic Approach at Initial Diagnosis (N=213)

Parameter	Global Study Population (N=213)	De novo aDTC	Recurrent / Progressive eDTC	p-Value
Surgery, Patients No. (%)	209 (98.1)	111 (100.0)	98 (100.0)	0.1263
Neck dissection	157 (75.1)	86 (77.5)	71 (72.4)	0.4014
Surgery result, Patients No. (%)				<0.0001 *
R0	143 (68.4)	66 (59.5)	77 (78.6)	
R1	29 (13.9)	16 (14.4)	13 (13.3)	
R2	23 (11.0)	22 (19.8)	1 (1.0)	
Metastases resection	8 (3.8)	5 (4.5)	3 (3.1)	
Other ⁽¹⁾	5 (2.4)	1 (0.9)	4 (4.1)	
Unknown ⁽²⁾	1 (0.5)	1 (0.9)	..	
RAI treatment, Patients No. (%)	190 (89.2)	97 (84.3)	93 (94.9)	0.0134 *
Administered dose per intervention, Patients No, Median (Q1-Q3), mCi	189 150.0 (100.0 - 150.0)	97 150.0 (130.0 - 155.0)	92 104.0 (100.0 - 150.0)	<0.0001 *
Cumulative RAI dose per intervention, Patients No., Median (Q1-Q3), mCi				
First	189 150.0 (100.0 - 150.0)	97 150.0 (130.0 - 155.0)	92 104.0 (100.0 - 150.0)	<0.0001 *
Second	116 300.0 (250.0 - 325.0)	67 300.0 (271.0 - 350.0)	49 250.0 (200.0 - 300.0)	<0.0001 *
Third	57 450.0 (400.0 - 500.0)	40 450.0 (427.0 - 519.0)	17 343.0 (300.0 - 400.0)	<0.0001 *
Use pre- RAI hrTSH per intervention, ⁽³⁾ Patients No. (%), Yes / No				
First	46 (24.2) / 136 (71.6)	28 (28.9) / 65 (67.0)	18 (19.4) / 71 (76.3)	0.1251
Second	33 (17.4) / 73 (38.4)	24 (24.7) / 37 (38.1)	9 (9.7) / 36 (38.7)	0.0335

Initial Clinical and Treatment Patterns of Advanced Differentiated Thyroid Cancer. ERUDIT Study.

Juan Antonio Vallejo Casas^{1*}; Marcel Sambo^{2*}; Carlos López López³ and Manuel Durán-Poveda⁴ on behalf of the ERUDIT Study group

Parameter	Global Study Population (N=213)	De novo aDTC	Recurrent / Progressive eDTC	p-Value
Third	18 (9.5) / 33 (17.4)	14 (14.4) / 22 (22.7)	4 (4.3) / 11 (11.8)	0.4053
Most frequent response to RAI per intervention. ATA criteria, ⁽⁴⁾ Patients No. (%)				
First (Structural Incomplete)	117 (61.6)	77 (79.4)	40 (43.0)	<0.0001 *
Second (Structural Incomplete)	71 (37.4)	52 (53.6)	19 (20.4)	<0.0001 *
Third (Structural Incomplete)	44 (23.2)	34 (35.1)	10 (10.8)	0.0429 *
Radiotherapy,⁽⁵⁾ Patients No. (%)	21 (9.9)	17 (14.8)	4 (4.5)	0.0090 *
Administered dose, Cases No,	19	16	3	0.0288 *
Median (Q1-Q3), Gy	30.0 (20.0 - 44.0)	30.0 (20.0 - 40.0)	54.0 (46.0 - 70.0)	
Response to radiotherapy, ⁽⁶⁾ Patients No. (%)	21	17	4	0.4027
Complete Response	1 (4.8)	1 (5.9)	0 (0.0)	
Partial Response	2 (9.5)	1 (5.9)	1 (25.0)	
Stable Disease	11 (52.4)	10 (58.8)	1 (25.0)	
Progression Disease	4 (19.0)	3 (17.6)	1 (25.0)	
Not evaluable / No applicable	3 (14.3)	2 (11.8)	1 (25.0)	

(1): Resection of other lesions like adenopathies or metastases. (2): Records could not be retrieved from the electronic Case Report Form. (3): Following standard practice in Spain and Portugal, patients not receiving hrTSH prior to RAI, were deprived of LT4. (4): Haugen et al., 2016.⁽¹⁾ (5): The usage of other locoregional ablative techniques was anecdotal. (6): Parameters based on objective response followed the standard RECIST v1.1 definition while actual data was retrieved as it was recorded in the patients' medical records. As such, objective response rate is the sum of complete response plus partial response according to physician-reported best response to treatment. Stable disease and progressive disease also followed this general guidance. NA: Not applicable. R0: Microscopic complete resection. R1: Macroscopic resection with microscopic residual tumour. R2: Gross macroscopic residual tumour. (*): Statistically significant (p<0.05).